首页 > 市场调查报告书 > 製药

糖尿病

市场调查报告书

商品编码

1408981

全球糖尿病视网膜病变市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 131 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，全球糖尿病视网膜病变市场的市场规模将从 2022 年的 86.1 亿美元达到近 150.8 亿美元，2023-2030 年研究期间CAGR为 7.26%。

糖尿病视网膜病变是一种与糖尿病相关的眼部疾病，会影响视网膜（眼睛后部的感光组织）。它是糖尿病患者视力障碍的一个主要原因。随着与糖尿病相关的血糖水平升高对视网膜内的小血管造成损害，这种情况逐渐发展。

市场动态

糖尿病视网膜病变市场由几个关键因素驱动，其中全球糖尿病盛行率不断上升是主要原因。由于糖尿病仍然是一个重大的健康问题，发病率的上升导致越来越多的人面临糖尿病视网膜病变的风险，从而推动了对诊断和治疗解决方案的需求。诊断工具和影像技术的技术进步对增强早期检测能力的贡献显而易见。对定期眼部筛检的重视以及将远距医疗纳入筛检计画进一步扩大了可近性，特别是在服务不足的地区。药物创新，包括玻璃体内注射和针对糖尿病黄斑水肿的药物，透过提供有效的管理选择，促进市场的发展。医疗保健专业人员和患者对眼睛健康在糖尿病管理中的重要性的认识不断提高，鼓励增加筛检和早期介入。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球糖尿病视网膜病变市场的各个细分市场进行了包容性评估。糖尿病视网膜病变产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲糖尿病视网膜病变市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。糖尿病视网膜病变市场的主要参与者包括拜耳公司、艾伯维公司、诺华公司、Oxurion NV、Sirnaomics、Alimera Sciences、Ampio Pharmaceuticals Inc.、BCNPeptides、Kowa Company Ltd.和Genentech, Inc.。查看竞争格局，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：糖尿病视网膜病变公司的竞争格局

糖尿病视网膜病变市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Bayer AG

公司简介
公司收入
产品
最近的发展

ABBVIE INC.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Oxurion NV

公司简介
公司收入
产品
最近的发展

Sirnaomics

公司简介
公司收入
产品
最近的发展

Alimera Sciences

公司简介
公司收入
产品
最近的发展

Ampio Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

BCNPeptides

公司简介
公司收入
产品
最近的发展

Kowa Company Ltd.

公司简介
公司收入
产品
最近的发展

Genentech Inc.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113274

The global demand for Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.08 BN by 2030 from USD 8.61 BN in 2022 with a CAGR of 7.26% under the study period 2023 - 2030.

Diabetic retinopathy is an eye disease linked to diabetes, impacting the retina-the light-sensitive tissue at the back of the eye. It stands as a prominent cause of vision impairment among individuals with diabetes. The condition develops gradually as elevated levels of blood sugar associated with diabetes cause damage to the small blood vessels within the retina.

MARKET DYNAMICS

The diabetic retinopathy market is driven by several key factors, with the increasing global prevalence of diabetes being a primary contributor. As diabetes remains a significant health concern, the rising incidence contributes to a growing population at risk of diabetic retinopathy, propelling the demand for diagnostic and treatment solutions. The pivotal role of technological advancements in diagnostic tools and imaging techniques is evident in their contribution to enhancing early detection capabilities. The emphasis on regular eye screenings and the integration of telemedicine in screening programs further expands accessibility, particularly in underserved areas. Pharmaceutical innovations, including intravitreal injections and medications targeting diabetic macular edema, contribute to the market's development by offering effective management options. The heightened awareness among healthcare professionals and patients about the importance of eye health in diabetes management encourages increased screenings and early intervention.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic retinopathy. The growth and trends of diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Proliferative Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy

By Management

Anti-VEGF
Intraocular Steroid Injection
Laser Surgery
Vitrectomy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Diabetic Retinopathy market include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., and Genentech, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Management
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions
5.5 Non-proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions

6 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY MANAGEMENT

6.1 Overview by Management
6.2 Historical and Forecast Data
6.3 Analysis by Management
6.4 Anti-VEGF Historic and Forecast Sales by Regions
6.5 Intraocular Steroid Injection Historic and Forecast Sales by Regions
6.6 Laser Surgery Historic and Forecast Sales by Regions
6.7 Vitrectomy Historic and Forecast Sales by Regions

7 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DIABETIC RETINOPATHY COMPANIES

8.1. Diabetic Retinopathy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF DIABETIC RETINOPATHY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. ABBVIE INC.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Oxurion NV
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Sirnaomics
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Alimera Sciences
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Ampio Pharmaceuticals Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. BCNPeptides
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Kowa Company Ltd.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Genentech Inc.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments